etoposide has been researched along with sepantronium in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Altieri, DC; Bosari, S; Faversani, A; Lopergolo, A; Moro, GP; Rivadeneira, D; Schultz, DC; Tosi, D; Vaira, V | 1 |
| Huang, J; Liu, B; Lyu, H; Wang, J | 1 |
| Kok, MK; Nakagawa, T; Nishimura, R; Ong, SM; Saeki, K | 1 |
| Dizdar, L; Esposito, I; Ghadimi, MPH; Knoefel, WT; Krieg, A; Schlünder, PM; Vay, C | 1 |
4 other study(ies) available for etoposide and sepantronium
| Article | Year |
|---|---|
Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors.
Topics: Alternative Splicing; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; High-Throughput Screening Assays; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; MCF-7 Cells; Naphthoquinones; Paclitaxel; Receptor, ErbB-2; Survivin; Tumor Suppressor Protein p53 | 2014 |
Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Doxorubicin; Drug Synergism; Etoposide; HL-60 Cells; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Naphthoquinones; Survivin | 2015 |
YM155 enhances the cytotoxic activity of etoposide against canine osteosarcoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Proliferation; Dog Diseases; Dogs; Drug Synergism; Etoposide; Humans; Imidazoles; Mice; Naphthoquinones; Osteosarcoma; Survivin; Xenograft Model Antitumor Assays | 2019 |
Targeting abundant survivin expression in liposarcoma: subtype dependent therapy responses to YM155 treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Liposarcoma; Male; Middle Aged; Naphthoquinones; Prognosis; Retrospective Studies; Survival Rate; Survivin; Tumor Cells, Cultured | 2022 |